All In Biotech

Drug Trial Radar · NCT03906006

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects

A Single-Center, Randomized, Double-Blind, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of ABP-671 in Healthy Volunteers in the United States

Last checked: Nov 19, 2026Latest source record: Jul 29, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Oct 17, 2018

Primary completion

Jun 20, 2019

Study completion Jun 20, 2019

Sponsor

Lead sponsor
Atom Therapeutics Co., LtdIndustry
Sponsor type
Industry
First posted
Apr 8, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of ABP-671 administered orally in healthy volunteers.

Conditions

  • Gout
  • Hyperuricemia

Interventions

  • ABP-671Drug

    Drug: ABP-671, single oral dose

  • PlaceboOther

    Other: Placebo, single oral dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse eventsTime frame: baseline to 7 days
  2. Maximum tolerable doseTime frame: baseline to 7 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Celerion

    Tempe, Arizona

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.